Press releases
2024
28 November, 2024
Toleranzia AB appoints SKMG as new Certified Adviser
Toleranzia AB (publ) has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (“SKMG”) regarding the service as Certified Adviser...
25 November, 2024
Toleranzia AB publishes the Nomination Committee
Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2025. The Nomination Committee, which has...
22 October, 2024
Toleranzia receives approximately SEK 37 million through the warrants of series TO4 which were exercised to approximately 85 percent
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND...
21 October, 2024
Toleranzia AB: Interim report third quarter 2024
Three months, July 1 - September 30 Six months, January 1 - September 30 The "Company" or "Toleranzia" refers to Toleranzia AB with...
17 October, 2024
Last day of trading with warrants of series TO4 in Toleranzia is today, 17 October 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND...
16 October, 2024
Toleranzia brings forward the publication of the Q3 report for 2024
Toleranzia AB (the ”Company" or "Toleranzia") brings forward the publication of the interim report for the third quarter of 2024 to...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND...
2 October, 2024
Toleranzia submits a clinical trial application (CTA) for the drug candidate TOL2 for the treatment of myasthenia gravis
Toleranzia AB (the ”Company" or "Toleranzia") today announces that it has filed a CTA with the European Medicines Agency (EMA) for...
28 August, 2024
Toleranzia has received subscription commitments regarding the exercise of warrants of series TO4 corresponding to approximately 71.14 percent
Toleranzia AB (the ”Company" or "Toleranzia") has entered into subscription commitments with Flerie Invest AB, Zonda Partners AB...
23 August, 2024
Toleranzia AB: Interim report second quarter 2024
Three months, April 1 - June 30 Six months, January 1 - June 30 The "Company" or "Toleranzia" refers to Toleranzia AB with organization...
Toleranzia AB ("Toleranzia" or the "Company") hereby announces that the Company today entered into an agreement with Clinical Trial...
Toleranzia AB ("Toleranzia") hereby announces that the company has appointed Ann-Sofie Taube as CFO on an interim basis until further notice...
The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 19 June 2024. The meeting was conducted with...
31 May, 2024
Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis
Toleranzia previously reported the successful completion of a GLP-toxicology study of TOL2, a regulatory milestone for approval of an investigational new...
The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to the Annual General Meeting...
20 May, 2024
Toleranzia AB: Interim report first quarter 2024
Three months, January 1 - March 31· Operating profit/loss amounted to KSEK -1,641 (-1,988).· Cash flow from operating activities...
30 April, 2024
Toleranzia AB: Annual report for the financial year 2023
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2023. The reports are available on the company's (www.toleranzia.se)...
Correction: A MAR label was missing in the press release published on April 24, 2024. Consequently, Toleranzia hereby publishes a corrected version, which...
24 April, 2024
Toleranzia AB receives loan commitment of SEK 20 million
Toleranzia AB ("Toleranzia" or the "Company") has today signed an agreement with Flerie Invest AB including a loan commitment of SEK...
18 March, 2024
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program
Toleranzia AB has successfully completed a scientific advisory meeting with the German Medicines Agency, Paul Ehrlich Institut (PEI), which confirmed Toleranzia's...
23 February, 2024
Toleranzia AB – Year-End Report 2023
Three months, October 1 - December 31· Operating profit/loss (EBIT) amounted to KSEK -2,121 (-2,181).· Cash flow from operating...
15 January, 2024
Toleranzia successfully completes GLP toxicology study of TOL2
Toleranzia AB ("Toleranzia" or the "Company") today announces that the pivotal toxicology study, conducted under Good Laboratory Practice...
2023
Toleranzia AB announces today that the company has entered into an agreement with the contract manufacturer Curia (Scotland) Limited ("Curia")...
15 December, 2023
Toleranzia AB presents Nomination Committee
Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2024. The Nomination Committee, which has...
Toleranzia AB has successfully completed a scientific advisory meeting with the Danish Medicines Agency, DKMA, on the preclinical status and the company's...
27 October, 2023
Toleranzia AB: Interim report third quarter 2023
Three months, July 1 - September 30· Net sales amounted to -- KSEK (--)· Profit after financial items amounted to KSEK -1,099...
16 October, 2023
Toleranzia appoints Thomas Pålsson as new Chief Financial Officer
Toleranzia AB ("Toleranzia" or the "Company") announces today that Thomas Pålsson has been appointed as new Chief Financial Officer...
26 September, 2023
Toleranzia starts toxicology study of its lead drug candidate TOL2
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has started the regulatory GLP-toxicology study of its drug candidate...
15 September, 2023
Toleranzia announces outcome in rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG...
25 August, 2023
Toleranzia AB: Interim report second quarter 2023
Three months, April 1 - June 30· Net sales amounted to -- KSEK (--)· Profit after financial items amounted to KSEK -2 503...
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has finalized the development of an optimized drug product formulation...
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully completed the manufacturing steps of the GMP...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG...
The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 7 June 2023. The meeting was conducted with...
The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend the Annual General...
First quarter, 2023 Three months, January 1 - March 31 · Net sales amounted to -- KSEK (--) · Profit after financial items...
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2022. The reports are available on the company's (www.toleranzia.se)...
Toleranzia AB ("Toleranzia" or the "Company") announces today that the Company has been awarded a grant from Vinnova for a project...
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured a technical batch of TOL2. The...
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has filed a new patent application for the treatment of autoimmune...
24 February, 2023
Toleranzia AB - Year-End Report 2022
Fourth quarter 2022 Fourth quarter, 1 October – 31 December · Net sales amounted to -- KSEK (--) · Profit after financial...
12 January, 2023
Toleranzia AB presents Nomination Committee
Toleranzia AB (publ) publishes the Nomination Committee’s composition for the Annual General Meeting in 2023. The Nomination Committee, which has...
2022
27 December, 2022
Toleranzia selects Charles River Laboratories for the GLP toxicology study of its drug candidate TOL2
Toleranzia AB (publ) today announces that it has entered into an agreement with Charles River Laboratories (CRL) to conduct the GLP toxicology study on...
Toleranzia AB ("Toleranzia" or the "Company") today announces that it has successfully manufactured and evaluated a pilot batch of...
28 November, 2022
Statement from the Board of Directors of Toleranzia AB regarding Flerie Invest's mandatory bid
The Board of Directors of Toleranzia AB (publ) ("Toleranzia" or the "Company") recommends that the shareholders of Toleranzia do not...
14 November, 2022
Flerie Invest AB has announced a mandatory bid to the shareholders of Toleranzia AB
Flerie Invest AB ("Flerie Invest") announced on 2 November 2022 that Flerie Invest has increased its holding in Toleranzia AB ("Toleranzia"...
28 October, 2022
Toleranzia AB: Interim report 2022-01-01 – 2022-09-30
Third quarter 2022 Third quarter, 1 July – 30 September · Net sales amounted to -- KSEK (--) · Profit after financial...
26 August, 2022
Toleranzia AB: Interim report 2022-01-01 – 2022-06-30
Second quarter 2022 Second quarter, 1 April – 30 June · Net sales 0 SEK (0 SEK). · Profit/loss after financial items...
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has appointed Torbjörn Sannerstedt as its...
The Annual General Meeting of Toleranzia AB (publ), 556877-2866, (the "Company") took place today, 3 June 2022. The meeting was conducted with...
3 June, 2022
Positive results for Toleranzia's drug candidate TOL2 published in reputable scientific journal
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the results of preclinical studies with the Company's most...
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that it will participate in The 14th MGFA International Conference...
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Swedish Knowledge Foundation, KKS, has approved an application...
First quarter 2022 First quarter, 1 January – 31 March · Net sales 0 SEK (0 SEK). · Profit/loss after financial items...
The shareholders of Toleranzia AB (publ), 556877-2866, ("Toleranzia" or the "Company"), are hereby invited to attend the Annual General...
Toleranzia AB today publishes its annual report and auditors' report for the financial year 2021. The reports are available on the company's (www.toleranzia.se)...
28 March, 2022
Toleranzia secures access to materials for large-scale manufacturing of drug candidate TOL2
Toleranzia AB (publ) ("Toleranzia" or the "Company") today announces that the Company has taken additional steps to secure access to...
2021
11 November, 2021
Start of Toleranzia's planned clinical trial with TOL2 postponed due to global shortage of certain materials for production of the drug substance
Toleranzia AB (publ) today announces that the planned start of a first clinical study of its drug candidate TOL2 in patients with myasthenia gravis will...
10 November, 2021
Toleranzia appoints Ann-Charlotte Rosendahl as Chair of the Board
Toleranzia AB (publ) today announces that its Board of Directors has appointed Ann-Charlotte Rosendahl as new Chair of the Board, following the resignation...
21 September, 2021
Toleranzia AB (publ): Receives approximately SEK 42 million through fully subscribed directed share issue
Toleranzia AB (publ) (”Toleranzia” or the ”Company”) today announces the outcome of the directed share issue resolved upon by the...
20 September, 2021
Approximately 95.7 per cent of the warrants of series TO3 were subscribed and Toleranzia AB will receive approximately MSEK 27.5
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
16 September, 2021
Bulletin from the extraordinary general meeting in Toleranzia AB (publ) on 16 September 2021
The extra general meeting in Toleranzia AB (publ), reg. no. 556877-2866 (”Toleranzia” or ”the Company”), was held today on 16 September...
13 September, 2021
The last day for trading in the warrants of series TO3 in Toleranzia AB (publ) is today, 13 September 2021
Today, 13 September 2021, is the last day for trading in warrants of series TO3 in Toleranzia AB (publ) ("Toleranzia" or the "Company")...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...
Toleranzia AB ("Toleranzia" or the "Company") has conducted so called “consistency batches” at the contract manufacturer...
10 August, 2021
Notice of extraordinary general meeting of Toleranzia AB (publ)
The shareholders of Toleranzia AB (publ), org.nr 556877-2866 ("Toleranzia" or the "Company"), are hereby convened to an extraordinary...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA...